Bateman ED, Khan AH, Xu Y, et al. - Researchers sought to conduct an indirect treatment comparison (ITC) between five biologic treatment options that are available for use in patients with uncontrolled persistent asthma: three interleukin (IL)-5 antagonists, which either bind to the anti-IL-5 ligand (mepolizumab, reslizumab) or to the IL-5 receptor (benralizumab);one anti-immunoglobulin E (anti-IgE) therapy (omalizumab); and one anti-IL-4/IL-13 therapy (dupilumab). Searching Embase, MEDLINE, and Cochrane Central Register of Controlled Trials (CENTRAL), they included 14 RCTs in the analyses. Outcomes revealed correlation of dupilumab with lower severe asthma exacerbation rates vs anti-IL-5s and omalizumab. Further, greater improvements in lung function were observed in association with dupilumab vs anti-IL-5s and omalizumab.